Source: Annual Congress 2013 –Grand Round on diagnostic and therapeutic challenges in thoracic oncology: an interactive session
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Brunelli (Ancona, Italy). A case of marginally-operable NSCLC. Annual Congress 2013 –Grand Round on diagnostic and therapeutic challenges in thoracic oncology: an interactive session

Member's Comments

Michele Gallo - 12.10.2013 00:15
Very important contribution

Related content which might interest you: Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 A case study of oligometastatic lung adenocarcinoma Source: International Congress 2015 – Lung cancer: the need for a multidisciplinary approach - an interactive session Year: 2015 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 A rare choroidal metastasis in ALK+ non-small cell lung cancer (NSCLC) that responds to Crizotinib Source: International Congress 2019 – CCC Thoracic oncology Year: 2019 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 A rare involvement in a male patient with non-small cell lung carcinoma: breast metastasis Source: Eur Respir J 2005; 26: Suppl. 49, 538s Year: 2005 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012